BioCentury | Nov 19, 2020
Finance

Syncona enters kidney disease space with gene therapy newco Purespring

...diseases with gene therapy, it isn’t the first non-monogenic program within the firm’s portfolio. Syncona’s Gyroscope Therapeutics Ltd....
BioCentury | Sep 16, 2020
Deals

Sept. 15 Quick Takes: NIH consortium seeks schizophrenia biomarkers; plus Boehringer-Click, Takeda, Nestlé-Aimmune, 89bio, Cellinta, Cullinan Florentine, Bayer-Systems Oncology

...who joined in July, was CEO of Gyroscope Therapeutics Ltd....
BioCentury | Aug 8, 2020
Finance

Freeline, Checkmate make NASDAQ debuts as 2020 pads its record-setting IPO tally

...Biogen Inc. (NASDAQ:BIIB) acquired it last year for $877 million. Syncona-backed ocular gene therapy play Gyroscope Therapeutics Ltd....
BioCentury | Jun 30, 2020
Finance

Syncona’s Freeline mulls IPO after crossovers back gene therapy play

...Freeline is among a handful of gene therapy companies Syncona has launched. The firm created Gyroscope Therapeutics Ltd....
BioCentury | May 20, 2020
Management Tracks

Former Allergan execs join Merck spinout; plus Ping An ousts Tao, and updates from Mirati, Evox, Ardelyx, Akcea, Horama and more

...Montgomery as CMO, a new position. She was VP and head of clinical development at Gyroscope Therapeutics Ltd....
BioCentury | Mar 23, 2020
Product Development

Lilly trial slowdown could include Phase III GI candidate; Syncona among others acknowledging delays

...holdings with clinical programs include cell therapy company Autolus Therapeutics plc (NASDAQ:AUTL), Freeline Therapeutics Ltd., Gyroscope Therapeutics Ltd....
...Luteinizing hormone-releasing hormone Paul Bonanos, Associate Editor mirikizumab (LY3074828) Eli Lilly and Co. Syncona Ltd. ObsEva S.A. Autolus Therapeutics Ltd. Freeline Therapeutics Ltd. Gyroscope Therapeutics Ltd. Achilles...
BioCentury | Sep 3, 2019
Financial News

Gyroscope nets £50.4M to advance dry AMD gene therapy

...in the deal. Existing investor Cambridge Innovation Capital also participated, adding the remaining £2.4 million. Gyroscope Therapeutics Ltd.'s...
...Biotechnology Inc. (Seattle, Wash.) and VP of corporate affairs at Juno Therapeutics Inc. Stephen Hansen, Associate Editor GT005 Gyroscope Therapeutics Ltd. Syncona...
BioCentury | Sep 3, 2019
Financial News

Achilles adds £100M to move neoantigen T cell therapy into the clinic

...In contrast, Syncona itself largely funded the £50.4 million series B round for portfolio company Gyroscope Therapeutics Ltd....
BioCentury | Jun 29, 2019
Finance

Specialists and strong fundamentals must carry the sector in 3Q19

...$13.3 $51 (B) $64.3 Catalent Inc. (NASDAQ:CTLT) Paragon Bioservices Inc. 04/15/19 $1,200.0 NA NA $1,200.0 Gyroscope Therapeutics Ltd....
BioCentury | Jun 27, 2019
Product Development

Gene therapy’s next frontier lies beyond rare, monogenic diseases

...be relevant for the garden variety disease.” Sekar Kathiresan, Verve Therapeutics Inc. In dry AMD, Gyroscope Therapeutics Ltd....
...Axovant Gene Therapies Ltd. (NASDAQ:AXGT), Basel, Switzerland Broad Institute of MIT and Harvard, Cambridge, Mass. Gyroscope Therapeutics Ltd....
...AAV.7m8-aflibercept) AXO-Lenti-PD, OXB-102 brolucizumab (RTH258, esba1008) Eylea, VEGF Trap-Eye, aflibercept ophthalmic solution RGX-314 VY-AADC (VY-AADC01) AbbVie Inc. Adverum Biotechnologies Inc. Axovant Gene Therapies Ltd. Gyroscope Therapeutics Ltd. Hemera...
Items per page:
1 - 10 of 24
BioCentury | Nov 19, 2020
Finance

Syncona enters kidney disease space with gene therapy newco Purespring

...diseases with gene therapy, it isn’t the first non-monogenic program within the firm’s portfolio. Syncona’s Gyroscope Therapeutics Ltd....
BioCentury | Sep 16, 2020
Deals

Sept. 15 Quick Takes: NIH consortium seeks schizophrenia biomarkers; plus Boehringer-Click, Takeda, Nestlé-Aimmune, 89bio, Cellinta, Cullinan Florentine, Bayer-Systems Oncology

...who joined in July, was CEO of Gyroscope Therapeutics Ltd....
BioCentury | Aug 8, 2020
Finance

Freeline, Checkmate make NASDAQ debuts as 2020 pads its record-setting IPO tally

...Biogen Inc. (NASDAQ:BIIB) acquired it last year for $877 million. Syncona-backed ocular gene therapy play Gyroscope Therapeutics Ltd....
BioCentury | Jun 30, 2020
Finance

Syncona’s Freeline mulls IPO after crossovers back gene therapy play

...Freeline is among a handful of gene therapy companies Syncona has launched. The firm created Gyroscope Therapeutics Ltd....
BioCentury | May 20, 2020
Management Tracks

Former Allergan execs join Merck spinout; plus Ping An ousts Tao, and updates from Mirati, Evox, Ardelyx, Akcea, Horama and more

...Montgomery as CMO, a new position. She was VP and head of clinical development at Gyroscope Therapeutics Ltd....
BioCentury | Mar 23, 2020
Product Development

Lilly trial slowdown could include Phase III GI candidate; Syncona among others acknowledging delays

...holdings with clinical programs include cell therapy company Autolus Therapeutics plc (NASDAQ:AUTL), Freeline Therapeutics Ltd., Gyroscope Therapeutics Ltd....
...Luteinizing hormone-releasing hormone Paul Bonanos, Associate Editor mirikizumab (LY3074828) Eli Lilly and Co. Syncona Ltd. ObsEva S.A. Autolus Therapeutics Ltd. Freeline Therapeutics Ltd. Gyroscope Therapeutics Ltd. Achilles...
BioCentury | Sep 3, 2019
Financial News

Gyroscope nets £50.4M to advance dry AMD gene therapy

...in the deal. Existing investor Cambridge Innovation Capital also participated, adding the remaining £2.4 million. Gyroscope Therapeutics Ltd.'s...
...Biotechnology Inc. (Seattle, Wash.) and VP of corporate affairs at Juno Therapeutics Inc. Stephen Hansen, Associate Editor GT005 Gyroscope Therapeutics Ltd. Syncona...
BioCentury | Sep 3, 2019
Financial News

Achilles adds £100M to move neoantigen T cell therapy into the clinic

...In contrast, Syncona itself largely funded the £50.4 million series B round for portfolio company Gyroscope Therapeutics Ltd....
BioCentury | Jun 29, 2019
Finance

Specialists and strong fundamentals must carry the sector in 3Q19

...$13.3 $51 (B) $64.3 Catalent Inc. (NASDAQ:CTLT) Paragon Bioservices Inc. 04/15/19 $1,200.0 NA NA $1,200.0 Gyroscope Therapeutics Ltd....
BioCentury | Jun 27, 2019
Product Development

Gene therapy’s next frontier lies beyond rare, monogenic diseases

...be relevant for the garden variety disease.” Sekar Kathiresan, Verve Therapeutics Inc. In dry AMD, Gyroscope Therapeutics Ltd....
...Axovant Gene Therapies Ltd. (NASDAQ:AXGT), Basel, Switzerland Broad Institute of MIT and Harvard, Cambridge, Mass. Gyroscope Therapeutics Ltd....
...AAV.7m8-aflibercept) AXO-Lenti-PD, OXB-102 brolucizumab (RTH258, esba1008) Eylea, VEGF Trap-Eye, aflibercept ophthalmic solution RGX-314 VY-AADC (VY-AADC01) AbbVie Inc. Adverum Biotechnologies Inc. Axovant Gene Therapies Ltd. Gyroscope Therapeutics Ltd. Hemera...
Items per page:
1 - 10 of 24